(Q34655135)

3 August 2017

1 reference

title

Neuroleptic malignant syndrome and serotonin syndrome. (English)

1 reference

neuroleptic malignant syndrome

3 August 2017

0 references

1 reference

Koichi Nisijima

1

1 reference

3 August 2017

Katsutoshi Shioda

series ordinal

2

1 reference

3 August 2017

Tatsunori Iwamura

series ordinal

3

1 reference

3 August 2017

language of work or name

1 reference

1 January 2007

1 reference

Progress in Brain Research

3 August 2017

published in

1 reference

3 August 2017

volume

162

1 reference

3 August 2017

page(s)

81-104

1 reference

Neuroleptic Malignant Syndrome and Atypical Antipsychotic Drugs

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Neuroleptic malignant syndrome under treatment with antidepressants? A critical review

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Neuroleptic malignant syndrome: a unique association with a tricyclic antidepressant

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Myoclonus and ocular oscillations induced by L-tryptophan

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

'Neuroleptic malignant syndrome' without neuroleptics

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Neuroleptic malignant syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Treatment of neuroleptic malignant syndrome with dantrolene sodium: a case report

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Malignant hyperthermia

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Positron emission tomographic studies of changes in cerebral blood flow and oxygen metabolism in neuroleptic malignant syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Mutation analysis of the ryanodine receptor gene isoform 3 (RYR3) in recurrent neuroleptic malignant syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Toxic serotonin syndrome or neuroleptic malignant syndrome?

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

The serotonin syndrome and its treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and L-tryptophan

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Treatment of the serotonin syndrome with cyproheptadine.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or "Ecstasy").

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

The use of clonidine in the management of autonomic overactivity in neuroleptic malignant syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Sympathoadrenomedullary activity in the neuroleptic malignant syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Unusual reaction to suxamethonium chloride

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Neuroleptic malignant syndrome: a pathogenetic role for dopamine receptor blockade?

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Serotonin syndrome and drug combinations: focus on MAOI and RIMA

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Possible development of the serotonin syndrome in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

CYP2D6 HhaI genotype and the neuroleptic malignant syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

An animal behavior model for studying central serotonergic synapses

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Imaging of dopamine receptors with [123I]iodobenzamide single-photon emission-computed tomography in neuroleptic malignant syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Genetic predisposition to neuroleptic malignant syndrome : implications for antipsychotic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Porcine stress syndrome: an animal model for the neuroleptic malignant syndrome?

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Brain neurotransmitter changes in three patients who had a fatal hyperthermia syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Treatment of a mild form of neuroleptic malignant syndrome with oral diazepam.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Dantrolene--a review of its pharmacology, therapeutic use and new developments

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Hyperpyrexia and rhabdomyolysis after ecstasy (MDMA) intoxication

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

5-HT-uptake inhibition potentiates antinociception induced by morphine, pethidine, methadone and ketobemidone in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

MDMA induced hyperthermia: a survivor with an initial body temperature of 42.9 degrees C.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Evidence that 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI)-induced hyperthermia in rats is mediated by stimulation of 5-HT2A receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Serotonin syndrome: early management with cyproheptadine

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Serotonin syndrome. A clinical update

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Fatal toxic encephalitis occurring during iproniazid therapy in pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Death by "ecstasy": the serotonin syndrome?

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Neuroleptic malignant syndrome. Successful treatment with bromocriptine

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Neuroleptic malignant syndrome after venlafaxine

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Neuroleptic malignant syndrome: a study of CSF monoamine metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Does dantrolene influence central dopamine and serotonin metabolism in the neuroleptic malignant syndrome? A retrospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Cerebrospinal fluid levels of monoamine metabolites and gamma-aminobutyric acid in neuroleptic malignant syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Single photon emission computed tomography with 123I-IMP in three cases of the neuroleptic malignant syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Intravenous injection of levodopa is more effective than dantrolene as therapy for neuroleptic malignant syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Risperidone counteracts lethality in an animal model of the serotonin syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Potent serotonin (5-HT)(2A) receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Toxic serotonin syndrome successfully treated with electroconvulsive therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Abnormal CSF Monoamine Metabolism in Serotonin Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Diazepam and chlormethiazole attenuate the development of hyperthermia in an animal model of the serotonin syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Memantine, an NMDA antagonist, prevents the development of hyperthermia in an animal model for serotonin syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Neurologic effects of tryptophan in patients receiving a monoamine oxidase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Evidence for postsynaptic mediation of the hypothermic effect of 5-HT1A receptor activation

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Is the Predisposition to Neuroleptic Malignant Syndrome Genetically Transmitted?

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Effect of dantrolene on K(+)- and caffeine-induced dopamine release in rat striatum assessed by in vivo microdialysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Serotonin Syndrome Induced by Low-Dose Venlafaxine

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Sulpiride increases and dopamine decreases intracranial temperature in rats when injected in the lateral hypothalamus: an animal model for the neuroleptic malignant syndrome?

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Lithium and serotonin function: implications for the serotonin hypothesis of depression

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: most antidepressants selectively block norepinephrine uptake

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

The Treatment of Neuroleptic Malignant Syndrome are Dantrolene and Bromocriptine Useful Adjuncts to Supportive Care?

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Dantrolene use in 3,4-methylenedioxymethamphetamine (ecstasy)-mediated hyperthermia

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Extracellular serotonin, dopamine and glutamate levels are elevated in the hypothalamus in a serotonin syndrome animal model induced by tranylcypromine and fluoxetine

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

An overdose of ecstasy. A role for dantrolene

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Prospective evaluation of circulatory levels of catecholamines and serotonin in neuroleptic malignant syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

The serotonin syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Development of an animal model for neuroleptic malignant syndrome: heat-exposed rabbits with haloperidol and atropine administration exhibit increased muscle activity, hyperthermia, and high serum creatine phosphokinase level

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Biochemical alterations during medication withdrawal in Parkinson's disease with and without neuroleptic malignant-like syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Serotonin syndrome after small doses of citalopram or sertraline

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

A rationale for NMDA receptor antagonist therapy of the neuroleptic malignant syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Possible central effect of dantrolene sodium in neuroleptic malignant syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

Successful treatment of the toxic serotonin syndrome with chlorpromazine

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2806%2962006-2

7 January 2021

10.1016/S0079-6123(06)62006-2

Identifiers

DOI

1 reference

3 August 2017

1 reference